To this end, this paper presents a modelling study that quantified the financial impacts of expanding access to PD1/PD-L1 inhibitors as first-line monotherapy for advanced unresectable NSCLC in patients with wildtype epidermal growth factor receptor (EGFR) PD-L1 tumoural proportion score (TPS) ≥50%. This evidence concerns the gene EGFR and non-small cell lung carcinoma.